Incorporation of pseudocapsule presence into a modified Clear Cell Likelihood Score (m-ccLS) was associated with a greater than 11 percent higher AUC in differentiating benign and malignant renal masses on mpMRI, according to a new study.
|Articles|April 24, 1996
Stock drop nixes AMI public offering
A secondary stock offering by MRI contrast developer AdvancedMagnetics was canceled due to a drop in the firm's share price,the company said earlier this month. Share prices of AdvancedMagnetics have fallen steadily this year, from $27.50 in earlyJanuary
Advertisement
A secondary stock offering by MRI contrast developer AdvancedMagnetics was canceled due to a drop in the firm's share price,the company said earlier this month. Share prices of AdvancedMagnetics have fallen steadily this year, from $27.50 in earlyJanuary to around $21 a share last week. Advanced Magnetics hadhoped to sell 1.35 million shares.
The Cambridge, MA, company also took a hit when it releasedsecond-quarter financial results last week. Advanced Magneticsposted a net loss for the quarter (end-March) of $2.4 millionon sales of $476,000, compared with net income of $3.3 millionand revenues of $6.2 million in the same period last year.
The company said that last year's quarterly revenues were higherdue to a $5 million licensing payment from Berlex Laboratoriesfor U.S. and Canadian rights to its Feridex IV liver agent. AdvancedMagnetics will receive another $5 million when Feridex receivesFood and Drug Administration approval. AMI received an approvableletter for Feridex earlier this year (SCAN 2/14/96).
Advertisement
Related to this article
For patients with hepatocellular carcinoma (HCC), perfusion beyond tumor margin on contrast-enhanced ultrasound that exceeds gray-scale ultrasound tumor measurement by 5 mm is associated with a 76 percent higher risk of worse recurrence-free survival, according to newly published research.
In the latest episode of his “Interventional Radiology in Focus” series, Mina Makary, MD, discusses the utility of prostatic artery embolization for treating benign prostatic hyperplasia, key imaging considerations and pertinent technique pearls to help facilitate optimal outcomes.
The AI-powered SwiftSight Body Composition software reportedly provides automated quantification of muscle and adipose tissue after a brief MRI scan.
In the second of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss how to handle disagreements with adjunctive AI in breast imaging, whether to include AI assessments in PACS, and whether patients should pay for the use of adjunctive AI.
Has the barrage of passwords, PINs and authenticator apps gone around the bend to a point where it hampers efficiency and productivity?
Catch up on the top radiology content of the past week.
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Body Composition Analysis
2
Study Shows Impact of Key mpMRI Features for Enhancing Assessment of Renal Masses
3
Tumor Margin Marker on Contrast-Enhanced Ultrasound May Predict Worse Outcomes in Patients with HCC
4
Interventional Radiology in Focus: A Closer Look at Prostatic Artery Embolization for Benign Prostatic Hyperplasia
5